This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SALVI, M. Articles by WALL, J. R. Search for Related Content PubMed PubMed Citation Articles by SALVI, M. Articles by WALL, J. R.

Affinity Purification of Orbital Membrane Antigens for the Study of the Pathogenesis of Graves’ Ophthalmopathy

Thyroid Unit, Montreal General Hospital Research Institute Montreal, Quebec, Canada H3G 1A4

Address all correspondence and requests for reprints to: Dr. J. R. Wall, Thyroid Unit, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4 Canada.

We characterized 22 human monoclonal antibodies (MCAB) reactive with human orbital antigens. Most of these monoclonal antibodies had variable degrees of reactivity with eye muscle, orbital connective tissue, thyroid, and extrathyroid tissue preparations when tested in an enzyme-linked immunosorbent assay (ELISA). Eight of the MCABs, selected on the basis of their reactivity with human eye muscle or orbital connective tissue antigens, were used to affinity purify orbital membrane antigens. All purified fractions were tested in the ELISA for reactivity with the MCAB used for their purification. Four of the purified antigens with a high reactivity were not proteins. To increase the specificity of the reactivity of serum autoantibodies with affinity-purified antigens, we developed a competitive binding ELISA in which the MCAB-immunoglobulin was directly labeled with alkaline phosphatase. We tested the serum of 24 patients with Graves’ ophthalmopathy, 10 patients with a history of Graves’ hyperthyroidism and no eye disease, 14 patients with Hashimoto’s thyroiditis without eye disease, 8 patients with other nonautoimmune thyroid disorders, and 20 normal subjects for reactivity with an affinity-purified nonprotein orbital antigen. The levels of serum autoantibodies against this antigen in patients with Graves’ ophthalmopathy were significantly higher than those in normal subjects or patients with Graves’ hyperthyroidism with no eye disease. Although unlikely to be of primary pathogenetic significance, it is possible that levels of this antibody in patients with Graves’ ophthalmopathy may reflect the extent of orbital inflammation and, therefore, be useful as a clinical marker.

^* This work was supported by Medical Research Council (Canada) Grant MT-698 and NIH Grant EYO-5062-01A1 from the NEI.

Received September 10, 1987.